These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22164410)

  • 41. Advanced glycosylation end products in diabetic renal and vascular disease.
    Bucala R; Vlassara H
    Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development.
    Abdulahad DA; Westra J; Limburg PC; Kallenberg CG; Bijl M
    Autoimmun Rev; 2010 Aug; 9(10):661-5. PubMed ID: 20546955
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Advanced glycation end products and hyperglycaemia].
    Omsland TK; Bangstad HJ; Berg TJ; Kolset SO
    Tidsskr Nor Laegeforen; 2006 Jan; 126(2):155-8. PubMed ID: 16415936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphorylation of pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus.
    Ding Y; Kantarci A; Badwey JA; Hasturk H; Malabanan A; Van Dyke TE
    J Immunol; 2007 Jul; 179(1):647-54. PubMed ID: 17579087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New biomarkers of Maillard reaction damage to proteins.
    Wells-Knecht KJ; Brinkmann E; Wells-Knecht MC; Litchfield JE; Ahmed MU; Reddy S; Zyzak DV; Thorpe SR; Baynes JW
    Nephrol Dial Transplant; 1996; 11 Suppl 5():41-7. PubMed ID: 9044306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hyperglycemia and glycation in diabetic complications.
    Negre-Salvayre A; Salvayre R; Augé N; Pamplona R; Portero-Otín M
    Antioxid Redox Signal; 2009 Dec; 11(12):3071-109. PubMed ID: 19489690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
    Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
    Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.
    Osawa T; Kato Y
    Ann N Y Acad Sci; 2005 Jun; 1043():440-51. PubMed ID: 16037265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced glycation end-products and the progress of diabetic vascular complications.
    Jakus V; Rietbrock N
    Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycation products and the pathogenesis of diabetic complications.
    Brownlee M
    Diabetes Care; 1992 Dec; 15(12):1835-43. PubMed ID: 1464241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gelatin as a convenient surrogate protein to model the in vitro effects of advanced glycation end-product formation.
    Pringle NA; van de Venter M; Koekemoer TC
    Exp Dermatol; 2018 Nov; 27(11):1309-1311. PubMed ID: 30136316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Protein glycation as a pathological mechanism in diabetes].
    Simm A; Navarrete-Santos A; Hofmann B; Bushnaq H; Nass N
    Z Gerontol Geriatr; 2012 Feb; 45(2):95-9. PubMed ID: 22350390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pathophysiologic aspects of diabetic angiopathy].
    Wautier JL; Wautier MP
    Diabetes Metab; 1999 Jun; 25 Suppl 3():21-6. PubMed ID: 10421989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local inflammatory reactions in patients with diabetes and periodontitis.
    Sonnenschein SK; Meyle J
    Periodontol 2000; 2015 Oct; 69(1):221-54. PubMed ID: 26252411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.
    Madonna R; Balistreri CR; Geng YJ; De Caterina R
    Vascul Pharmacol; 2017 Mar; 90():1-7. PubMed ID: 28137665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation.
    Zhang Y; Luo Z; Ma L; Xu Q; Yang Q; Si L
    Int J Mol Med; 2010 May; 25(5):729-34. PubMed ID: 20372816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Advanced glycosylation end products (AGE): new toxins?].
    Boulanger E; Dequiedt P; Wautier JL
    Nephrologie; 2002; 23(7):351-9. PubMed ID: 12500421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy?
    Cohen MP
    J Diabet Complications; 1988; 2(4):214-7. PubMed ID: 2976766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.